Programs and Projects

Prostate Cancer Clinical Trials - University of Arizona (Multicenter Sites)

Agent: Selenium yeast
Contact: Frederick Ahmann, M.D.
DCP Program Director: Howard Parnes, M.D.

The purpose of this study is to see if an oral medication containing selenized yeast can reduce the prevalence of prostate cancer in men with an elevated prostate specific antigen (PSA). It will also be necessary that those taking part in the study have had a negative biopsy for prostate cancer. Patients will receive this medication for up to 57 months. The multicenter study is being conducted under the auspices of the University Arizona at Tucson. Investigators are actively accruing participants to this trial.

[This is a small phase 3 randomized double-blind placebo controlled multicenter trial of selenized yeast for the chemoprevention of prostate cancer in subjects with elevated PSA and a negative biopsy for prostate cancer. The primary endpoint (s) are PSA velocity and biopsy detected prostate cancer at 57 months.]